(Q37329141)

19 August 2017

1 reference

title

Fenofibrate: treatment of hyperlipidemia and beyond (English)

1 reference

19 August 2017

1 reference

Robert S Rosenson

1

1 reference

19 August 2017

publication date

1 November 2008

1 reference

Expert Review of Cardiovascular Therapy

19 August 2017

published in

1 reference

19 August 2017

volume

6

1 reference

19 August 2017

issue

10

1 reference

19 August 2017

page(s)

1319-1330

1 reference

Standards of medical care in diabetes--2008.

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Global and societal implications of the diabetes epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Baseline achievement of lipid goals and usage of lipid medications in patients with diabetes mellitus (from the Veterans Affairs Diabetes Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Glucose, lipid, and blood pressure control in Australian adults with type 2 diabetes: the 1999-2000 AusDiab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Effects of peroxisome proliferator-activated receptors on lipoprotein metabolism and glucose control in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Individual and combined effects of peroxisome proliferator-activated receptor and {gamma} agonists, fenofibrate and rosiglitazone, on biomarkers of lipid and glucose metabolism in healthy nondiabetic volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men - a nuclear magnetic resonance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Effect of fibrates on postprandial remnant-like particles in patients with combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Mice lacking osteopontin exhibit increased left ventricular dilation and reduced fibrosis after aldosterone infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Rosuvastatin in older patients with systolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Effects of fenofibrate on high-density lipoprotein particle size in patients with hyperlipidemia: a randomized, double-blind, placebo-controlled, multicenter, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Normalization of metabolic syndrome using fenofibrate, metformin or their combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Field of confusion: future prospects for fibrate therapy in cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Correction to the FIELD study report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Safety considerations with fibrate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Effects of fibrates on metabolism of statins in human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

The effect of gemfibrozil on the pharmacokinetics of rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

The effects of multiple doses of fenofibrate on the pharmacokinetics of pravastatin and its 3alpha-hydroxy isomeric metabolite

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.10.1319

10.1586/14779072.6.10.1319

21 January 2018

Identifiers

DOI

1 reference

19 August 2017

1 reference